Results 161 to 170 of about 10,515,708 (302)

Editorial: Ten Years of Press Start [PDF]

open access: yes
Editorial for the May 2024 ...
Gómez, Sebastián   +12 more
core  

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

open access: yesMolecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Editorial: March 2019 (Vol. 5, Issue 1)

open access: yes, 2019
Over the past year, we’ve had a change of hands from our founder, Matt Barr, to our new editor-in-chief, Mahli-Ann Butt. We’ve taken some extra time to put together this issue with great pride and care.
Thomson, Reece   +7 more
core  

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

open access: yesMolecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Start-ups’ scaling-up strategies at the regional periphery

open access: yes
 Purpose – Our understanding of the strategies that lead to the success of start-ups when they scale-up is limited when it occurs at the regional periphery.
Christian Felzensztein (18625205)   +1 more
core   +1 more source

Rapid Start-Up Characteristics of Anammox under Different Inoculation Conditions. [PDF]

open access: yesInt J Environ Res Public Health, 2023
Tan Q, Xia S, Xu W, Jian Y.
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy